Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (161-170 of 248) with videos related to

Pageof 25
Sort By:
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2020
Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With EnzalutamideChristos E Kyriakopoulos, Elisabeth I Heath, Anna Ferrari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
CA: a Cancer Journal for Clinicians|May 23, 2019
The current state of molecular testing in the treatment of patients with solid tumors, 2019Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, et al.
Theranostics|May 8, 2023
Selective ablation of TRA-1-60<sup>+</sup> pluripotent stem cells suppresses tumor growth of prostate cancerJordan M White, Nicholas Ramos, Allen-Dexter Saliganan, et al.
Cancer|August 11, 2023
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkersBassel Nazha, Tony Zhuang, Sharon Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumorsPatricia M Lorusso, Martin J Edelman, Susan L Bever, et al.
The Oncologist|January 24, 2013
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, David C Smith, et al.
Cancer Research Communications|September 25, 2024
Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-TMichael C Brown, Vincent M D'Anniballe, David Boczkowski, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Pageof 25

Showing results (161-170 of 248) with videos related to

Sort By:
Pageof 25
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2020
Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With EnzalutamideChristos E Kyriakopoulos, Elisabeth I Heath, Anna Ferrari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
CA: a Cancer Journal for Clinicians|May 23, 2019
The current state of molecular testing in the treatment of patients with solid tumors, 2019Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, et al.
Theranostics|May 8, 2023
Selective ablation of TRA-1-60<sup>+</sup> pluripotent stem cells suppresses tumor growth of prostate cancerJordan M White, Nicholas Ramos, Allen-Dexter Saliganan, et al.
Cancer|August 11, 2023
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkersBassel Nazha, Tony Zhuang, Sharon Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumorsPatricia M Lorusso, Martin J Edelman, Susan L Bever, et al.
The Oncologist|January 24, 2013
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, David C Smith, et al.
Cancer Research Communications|September 25, 2024
Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-TMichael C Brown, Vincent M D'Anniballe, David Boczkowski, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Pageof 25